European Society of Human Reproduction and Embryology (ESHRE) 40th Annual Meeting

Having close family members with endocrine diseases, including type 2 diabetes (T2D), thyroid diseases, and polycystic ovary syndrome (PCOS), appears to increase the risk of pregnancy losses in a first-of-a-kind study presented at ESHRE 2024.

In the treatment of women with endometriosis-associated pain, relugolix combination has a risk-benefit profile that is more favourable than that of monotherapy, due to the latter contributing to increased vasomotor symptoms and substantial bone mineral density (BMD) loss, as shown in a study.

The use of intravenous immunoglobulin (IVIG) plus prednisolone does not appear to increase conception rates among women with recurrent pregnancy loss who are undergoing assisted reproductive technology (ART), according to a study.

In a combined analysis of 3 phase III randomized trials presented at ESHRE 2024, a single dose of 150 µg or 100 µg of corifollitropin alfa is found to provide an ovarian response equivalent to daily doses of 300 IU or 297 IU of follitropin beta, respectively, during a single IVF cycle

Women with ovarian hyperstimulation syndrome (OHSS) are at higher risk of experiencing postpartum haemorrhage, large birthweight, neonatal respiratory distress syndrome, and intraventricular haemorrhage, suggests a study presented at ESHRE 2024.

Hysterosalpingography (HSG) with an oil-based contrast medium yields a significantly higher rate of ongoing pregnancy and live birth than HSG with a water-soluble contrast medium, according to a study presented at ESHRE 2024.

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.

Dual triggering with gonadotropin-releasing hormone agonist (GnRHa) and human chorionic gonadotropin (hCG) was not superior to GnRHa alone in terms of mature oocyte retrieval for elective fertility preservation, according to a study presented at ESHRE 2024.

A study presented at ESHRE 2024 shows that increased exposure to fine particulate matter (PM2.5 and PM10) air pollution prior to oocyte collection (OPU) or frozen embryo transfer (FET) during in vitro fertilization (IVF) is associated with a reduction in live birth rates (LBRs) in subsequent FETs.

In the phase II OXOART2 trial presented at ESHRE 2024, the first-in-class, non-hormonal, oral agent OXO-001 increases implantation and pregnancy rates in infertile women ≤40 years undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).